Centessa Pharmaceuticals plc (NASDAQ:CNTA) Sees Significant Growth in Short Interest

Centessa Pharmaceuticals plc (NASDAQ:CNTA) was the target of a significant growth in short interest in the month of February. As of February 15th, there was short interest totalling 4,150,000 shares, a growth of 36.1% from the January 31st total of 3,050,000 shares. Based on an average daily trading volume, of 723,400 shares, the short-interest ratio is presently 5.7 days. Approximately 5.2% of the company’s shares are short sold.

Insider Activity at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, CEO Saurabh Saha sold 87,496 shares of the company’s stock in a transaction that occurred on Friday, December 6th. The shares were sold at an average price of $18.46, for a total value of $1,615,176.16. Following the completion of the sale, the chief executive officer now owns 575,661 shares of the company’s stock, valued at approximately $10,626,702.06. This represents a 13.19 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CTO Tia L. Bush sold 17,813 shares of the company’s stock in a transaction that occurred on Tuesday, December 17th. The shares were sold at an average price of $18.00, for a total transaction of $320,634.00. Following the completion of the sale, the chief technology officer now directly owns 147,615 shares of the company’s stock, valued at $2,657,070. The trade was a 10.77 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 446,682 shares of company stock worth $7,632,282 over the last ninety days. Company insiders own 11.59% of the company’s stock.

Institutional Trading of Centessa Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Jane Street Group LLC acquired a new stake in Centessa Pharmaceuticals in the third quarter valued at $2,834,000. Wellington Management Group LLP acquired a new stake in Centessa Pharmaceuticals in the third quarter valued at $1,609,000. State Street Corp acquired a new stake in Centessa Pharmaceuticals in the third quarter valued at $777,000. Ally Bridge Group NY LLC acquired a new stake in Centessa Pharmaceuticals in the third quarter valued at $4,951,000. Finally, GSA Capital Partners LLP lifted its stake in Centessa Pharmaceuticals by 66.1% in the third quarter. GSA Capital Partners LLP now owns 93,658 shares of the company’s stock valued at $1,498,000 after acquiring an additional 37,275 shares during the last quarter. Institutional investors and hedge funds own 82.01% of the company’s stock.

Centessa Pharmaceuticals Stock Up 3.9 %

Centessa Pharmaceuticals stock opened at $16.96 on Thursday. The company has a market cap of $2.24 billion, a P/E ratio of -11.08 and a beta of 1.53. Centessa Pharmaceuticals has a 1-year low of $7.75 and a 1-year high of $19.09. The company has a fifty day simple moving average of $16.50 and a 200 day simple moving average of $16.10. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on CNTA shares. TD Cowen started coverage on shares of Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating for the company. Guggenheim reaffirmed a “buy” rating on shares of Centessa Pharmaceuticals in a research report on Monday, February 10th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Centessa Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $25.83.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.